Phase 3 Clinical Trials With Primary Completion Dates in May 2023

This is a list of Phase 3 trials with primary completion dates in May 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
BLCO Bausch + Lomb Corporation 2023-05-01 Phase 3 NCT05360784 "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
BTAI BioXcel Therapeutics, Inc. 2023-05-01 Phase 3 NCT05271552 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
KOD Kodiak Sciences Inc. 2023-05-01 Phase 3 NCT04611152 A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
PRVB Provention Bio, Inc. 2023-05-01 Phase 3 NCT03875729 Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
SHIEF Shield Therapeutics plc 2023-05-01 Phase 3 NCT05126901 Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years